We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
04 May 2021 - 07 May 2021
Virtual Venue

Serious Infections Prevalent in ANCA-Associated Vasculitis

By LabMedica International staff writers
Posted on 08 Apr 2021
Print article
Image: Besides the typical periglomerular localization, a diffuse interstitial leukocyte infiltration is very common in ANCA-associated vasculitis (Photo courtesy of Dr. Franco Ferrario and Dr. Maria Pia Rastaldi)
Image: Besides the typical periglomerular localization, a diffuse interstitial leukocyte infiltration is very common in ANCA-associated vasculitis (Photo courtesy of Dr. Franco Ferrario and Dr. Maria Pia Rastaldi)
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) are among the rheumatic diseases with the highest mortality and morbidity, due to their major multi-organ involvement (lungs, kidneys) and their relapsing nature requiring aggressive immunosuppressive treatment.

Serious infections (SI) are common in patients with ANCA-AAV) like granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). Real-life data regarding their incidence and predisposing factors, after the introduction of B cell depleting agents, are limited while data quantifying the risk per treatment modality and year of the disease are missing.

Clinical Immunologists at the Hippokration General Hospital (Athens, Greece) and their colleagues conducted a multicenter, observational, retrospective study of patients with AAV followed in three referral centers in the Athens. The study included 162 patients with GPA (63%) and MPA (37%), males 51.9%, mean age 60.9 years, ΑΝCA+ 86%, and generalized disease 80%. During follow-up (891.2 patient-years, mean 5.4 years), 67 serious infections (SI) were recorded in 50 patients at an incidence rate of 7.5 /100 patient-years.

The team collected from each participant age, sex, date of diagnosis, diseases severity, disease activity at baseline (Birmingham Vasculitis Activity Score), ANCA serology, organ involvement, relapses, renal function [estimated glomerular filtration rate (eGFR) by CKD-EPI formula] during first induction of remission course) and treatment patterns (treatment types and duration for each treatment, both for induction and maintenance of remission as well as initial glucocorticoids (GC) dose at diagnosis). SI was defined those needing hospitalization or intravenous antibiotics as well as opportunistic infections. Given the high frequency of herpes zoster (HZ) in AAV population and the accompanying morbidity of this infection, all cases of HZ were considered as SI irrespective of hospitalization need.

The scientists found that the incidence of SI among patients undergoing induction treatment with cyclophosphamide was 19.34/100 patient-years compared with 11.34/100 for those whose induction regimen was with rituximab, for an incidence rate ratio for cyclophosphamide of 4.24. Patients with ANCA-associated vasculitides granulomatosis with polyangiitis and microscopic polyangiitis continued to have significant morbidity and mortality despite improvements in treatment, such as the wider use of rituximab, and the incidence of serious infections remained high.

Mean baseline estimated glomerular filtration rate (GFR) was 59.1 mL/min, and in almost a quarter of patients, the baseline GFR was below 30 mL/min. Renal replacement therapy and/or plasma exchange was needed at baseline for 6.2%. Site of infection was the respiratory tract in 45% of patients, and the gastrointestinal tract and urinary tract in 9% each. The infection was herpes zoster in 24% and bacteremia in 9%.

The authors concluded that in this real-life study of patients with AAV, the SI incidence was higher during cyclophosphamide compared to rituximab (RTX) induction while there was no difference between RTX and other agents used for maintenance therapy. Higher disease activity at baseline and need for plasmapheresis and/or dialysis were independent factors associated with an SI. The study was published on March 20, 2021 in the journal Arthritis Research & Therapy.

Related Links:
Hippokration General Hospital

Gold Supplier
SARS-COV-2 IgM/IgG Rapid Qualitative Test
GLINE-2019-nCoV IgM/IgG Rapid Qualitative Test
Wastewater SARS-CoV-2 RT-qPCR Kit
SARS-CoV-2 RT-qPCR Kit for Wastewater
Kantaro COVID-SeroKlir
Hematology Analyzer
DxH 560 AL

Print article
BIOHIT  Healthcare OY


Molecular Diagnostics

view channel
Image: The EZ DNA Methylation-Direct Kit (Photo courtesy of Zymo Research)

Leukocyte Epigenomics and Artificial Intelligence Predict Late-Onset Alzheimer’s Disease

Alzheimer’s Disease (AD) is the most common form of age-related dementia, accounting for 60%–80% of such cases. The disorder causes a wide range of significant mental and physical disabilities, with profound... Read more


view channel
Image: The Novodiag platform combines real-time PCR and microarray capabilities to provide high-level multiplexing (Photo courtesy of Mobidiag Ltd.)

Hologic to Acquire Mobidiag to Strengthen Diagnostic Testing Business

Hologic, Inc. (Marlborough, MA, USA) has signed a definitive agreement to acquire Mobidiag Ltd. (Espoo, Finland) in a USD 795 million transaction that will accelerate the global growth of Mobidiag’s differentiated... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.